Background Ranibizumab — a recombinant, humanized, monoclonal antibody Fab that
neutralizes all active forms of vascular endothelial growth factor A — has been evaluated for the …

Background We compared ranibizumab — a recombinant, humanized, monoclonal
antibody Fab that neutralizes all active forms of vascular endothelial growth factor A — with …

… Eligible participants were aged ≥18 years with diabetes mellitus (type 1 or 2), decreased
vision from DME (study eye BCVA, 20/40–20/320 Snellen equivalent using ETDRS testing), …

OBJECTIVE: Two similarly designed, phase-3 studies (VEGF Trap-Eye: Investigation of
Efficacy and Safety in Wet AMD [VIEW 1, VIEW 2]) of neovascular age-related macular …

Renal biopsies in 45 patients with insulin-dependent diabetes mellitus (IDDM) were examined
by semiquantitative light microscopy and quantitative electron microscopic stereologic …

… Financial Disclosure(s): The author(s) have made the following disclosure(s): David Brown
has received consulting fees from Genentech, Regeneron, Alcon, and Allergan and lecture …

Studies into the effects of ultrafine particles in the lung have shown adverse effects considered
to be due in part to the particle size. Air pollution particles (PM 10 ) are associated with …

… Brown MD 1 § , Quan Dong Nguyen MD, MSc 2 § , Dennis M. Marcus MD 3 , David S. Boyer
MD 4 , Sunil … QD Nguyen, DM Brown, DM Marcus, et al., RISE and RIDE Research Group …

… 2 diabetes mellitus … diabetes mellitus worldwide is predicted to increase the number of
afflicted individuals to 430 million by 2030. Chronic hyperglycemia secondary to diabetes mellitus …

As a result of bioassay–guided fractionation, betulinic acid, a pentacyclic triterpene, was
identified as a melanoma–specific cytotoxic agent. In follow–up studies conducted with athymic …